瑞舒伐他汀
临床注释ID
1451678240
药物名称(英)
rosuvastatin
变异单倍型
SLCO1B1*1, SLCO1B1*5, SLCO1B1*15
基因
SLCO1B1
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Toxicity
表现型类别
毒性
分数
105.5
PMID计数
8
计数的证据
9
表现型
他汀类药物相关性肌病
表现型(英)
statin-related myopathy
最新日期
2022/2/14 0:00:00
URL
https://www.pharmgkb.org/clinicalAnnotation/1451678240
专业人口(英)
专业人口
临床等位基因
id等位基因注释文本
1156 *15 The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.
1155 *5 The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.
1154 *1 The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.
临床证据
id证据的ID总结
4471 1183689623 Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.
4470 1448821127 Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.
4469 1448613086 Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.
4468 1183689645 Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.
4467 1450397924 Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.
4466 1451356526 Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.
4465 1451228540 Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.
4464 1451226140 Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.
4463 PA166262321 Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1
临床病史
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3